News

Deal Announcements

Aspyrian Therapeutics Raises Venture Capital Equity

Friday, July 31, 2015 5:32:00 AM PDT | VentureDeal
   San Diego, California  --  Cancer treatment developer Aspyrian Therapeutics has secured $4.25 million in new venture capital equity funding, according to an SEC regulatory filing.

Aspyrian is developing novel targeted therapies for cancer treatments utilizing antibody conjugates with tumor specific activation.

The technology was developed at the National Cancer Institute and uses near-infrared light to activate a toxic die attached to monoclonal antibodies.

The company has initiated a phase 1 study to treat recurrent head and neck cancer patients.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

Aspyrian previously raised $8.5 million in January 2015 from undisclosed investors.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1